Evaluation of Sex Hormones in Women with Polycystic Ovarian Syndrome

Hayder Sadeq  Mutashar; Anwar Shati  Mohammed; Hadeel Ali Shamkhi  Al-Husseinawi

Hayder Sadeq Mutashar Ministry of Health, Thi-Qar Health Directorate, Laboratory Department, Thi-Qar, Iraq
Anwar Shati Mohammed Ministry of Health, Thi-Qar Health Directorate, Laboratory Department, Thi-Qar, Iraq
Hadeel Ali Shamkhi Al-Husseinawi Ministry of Health, Thi-Qar Health Directorate, Laboratory Department, Thi-Qar, Iraq

Keywords: PCOS, Sex Hormones, Hormonal parameters, Kisspeptin, Reproductive health

Abstract

This study investigates the potential influence of the KISS1 gene polymorphism on Polycystic Ovary Syndrome (PCOS) and its associated hormonal parameters, including kisspeptin, testosterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and the LH/FSH ratio. PCOS affects 5% to 20% of women of reproductive age, and while genetic factors may play a role, the specific contributions of the KISS1 gene remain unclear. The study involved 200 women aged 17 to 40, with 100 diagnosed with PCOS and 100 in a control group. Blood samples were analyzed for hormone levels. Results indicated significantly elevated levels of kisspeptin, LH, testosterone, and the LH/FSH ratio in women with PCOS compared to controls, although FSH levels showed no significant differences. These findings suggest that elevated sex hormone levels may impact ovarian function in PCOS, highlighting the need for further research into the genetic mechanisms underlying this condition.

References

[1] R. Norman, R. Wu, and M. Stankiewicz, "Polycystic Ovary Syndrome," Nature Reviews Disease Primers, vol. 2, no. 1, pp. 1-18, May 2016.
[2] M. Mohd, M. Maqbool, M. A. Dar, and I. Mushtaq, "Polycystic Ovary Syndrome, a Modern Epidemic: An Overview," Journal of Drug Delivery and Therapeutics, vol. 9, no. 3, pp. 641-644, May 2019.
[3] R. P. Crespo, T. A. Bachega, B. B. Mendonça, and L. G. Gomes, "An Update of Genetic Basis of PCOS Pathogenesis," Archives of Endocrinology and Metabolism, vol. 62, no. 3, pp. 352-361, Jun. 2018.
[4] R. L. Thomson, J. D. Buckley, and G. D. Brinkworth, "Exercise for the Treatment and Management of Overweight Women with Polycystic Ovary Syndrome: A Review of the Literature," Obesity Reviews, vol. 12, no. 5, pp. e202-e210, May 2011.
[5] R. Garad, H. J. Teede, and L. Moran, "An Evidence-Based Guideline for Polycystic Ovary Syndrome," Australian Nursing Journal, vol. 19, no. 4, pp. 30-33, Oct. 2011.
[6] P. Lakhani and B. Sundaram, "Deep Learning at Chest Radiography: Automated Classification of Pulmonary Tuberculosis by Using Convolutional Neural Networks," Radiology, vol. 284, no. 2, pp. 574-582, Aug. 2017.
[7] P. Schmidt, Hitler's Interpreter: The Memoirs of Paul Schmidt. The History Press, Jun. 6, 2016.
[8] D. Lizneva, L. Suturina, W. Walker, S. Brakta, L. Gavrilova-Jordan, and R. Azziz, "Criteria, Prevalence, and Phenotypes of Polycystic Ovary Syndrome," Fertility and Sterility, vol. 106, no. 1, pp. 6-15, Jul. 2016.
[9] K. Katulski, A. Podfigurna, A. Czyzyk, B. Meczekalski, and A. D. Genazzani, "Kisspeptin and LH Pulsatile Temporal Coupling in PCOS Patients," Endocrine, vol. 61, pp. 149-157, Jul. 2018.
[10] P. A. Kołodziejski, E. Pruszyńska-Oszmałek, T. Wojciechowicz, M. Sassek, N. Leciejewska, et al., "The Role of Peptide Hormones Discovered in the 21st Century in the Regulation of Adipose Tissue Functions," Genes, vol. 12, no. 5, p. 756, May 17, 2021.
[11] F. S. Albalawi, M. H. Daghestani, and A. Eldali, "rs4889 Polymorphism in KISS1 Gene, Its Effect on Polycystic Ovary Syndrome Development and Anthropometric and Hormonal Parameters in Saudi Women," Journal of Biomedical Science, vol. 25, pp. 1-6, Dec. 2018.
[12] D. Panidis, D. Rousso, G. Koliakos, A. Kourtis, I. Katsikis, et al., "Plasma Metastin Levels Are Negatively Correlated with Insulin Resistance and Free Androgens in Women with Polycystic Ovary Syndrome," Fertility and Sterility, vol. 85, no. 6, pp. 1778-1783, Jun. 2006.
[13] A. H. Alnakash and N. K. Al-Tae, "Polycystic Ovarian Syndrome: The Correlation Between the LH/FSH Ratio and Disease Manifestations," Middle East Fertility Society Journal, vol. 12, no. 1, pp. 35-40, 2007.
[14] A. S. De Melo, S. V. Dias, R. de Carvalho Cavalli, V. C. Cardoso, H. Bettiol, et al., "Pathogenesis of Polycystic Ovary Syndrome: Multifactorial Assessment from the Foetal Stage to Menopause," Reproduction, vol. 150, no. 1, pp. R11-R24, Jul. 2015.
[15] B. Banaszewska, R. Z. Spaczynski, M. Pelesz, and L. Pawelczyk, "Incidence of Elevated LH/FSH Ratio in Polycystic Ovary Syndrome Women with Normo-and Hyperinsulinemia," Rocznik Akademii Medycznej Bialymstoku, vol. 48, no. 1, pp. 131-134, Jan. 2003.
[16] I. Matalliotakis, A. Kourtis, O. Koukoura, and D. Panidis, "Polycystic Ovary Syndrome: Etiology and Pathogenesis," Archives of Gynecology and Obstetrics, vol. 274, pp. 187-197, Jul. 2006.
[17] C. R. McCartney and J. C. Marshall, "Polycystic Ovary Syndrome," New England Journal of Medicine, vol. 375, no. 1, pp. 54-64, Jul. 7, 2016.
[18] S. K. Blank, C. R. McCartney, and J. C. Marshall, "The Origins and Sequelae of Abnormal Neuroendocrine Function in Polycystic Ovary Syndrome," Human Reproduction Update, vol. 12, no. 4, pp. 351-361, Jul. 2006.
[19] J. Farkas, A. Rigó, and Z. Demetrovics, "Psychological Aspects of the Polycystic Ovary Syndrome," Gynecological Endocrinology, vol. 30, no. 2, pp. 95-99, Feb. 2014.
[20] M. Beltramo, H. Dardente, X. Cayla, and A. Caraty, "Cellular Mechanisms and Integrative Timing of Neuroendocrine Control of GnRH Secretion by Kisspeptin," Molecular and Cellular Endocrinology, vol. 382, no. 1, pp. 387-399, Jan. 25, 2014.
[21] V. Pottapenjera, S. R. Rajanala, C. Reddy, A. Gangineni, K. Avula, et al., "Kisspeptin Modulates Luteinizing Hormone Release and Ovarian Follicular Dynamics in Pre-Pubertal and Adult Murrah Buffaloes," Frontiers in Veterinary Science, vol. 5, p. 149, Jul. 4, 2018.
[22] B. Umayal, N. V. Chandrasekharan, W. S. Wijesundera, and C. N. Wijeyaratne, "Polycystic Ovary Syndrome: Genetic Contributions from the Hypothalamic-Pituitary-Gonadal Axis," International Archives of Endocrinology and Clinical Research, vol. 4, no. 013, pp. 1-8, 2018.
[23] D. Pavičić Baldani, L. Škrgatić, Z. Bukvić Mokos, and I. Trgovčić, "Hyperandrogenemia Association with Acne and Hirsutism Severity in Croatian Women with Polycystic Ovary Syndrome," Acta Dermatovenerologica Croatica, vol. 21, no. 2, pp. 99-100, Aug. 23, 2013.
[24] D. S. Kiddy, P. S. Sharp, D. M. White, M. F. Scanlon, H. D. Mason, et al., "Differences in Clinical and Endocrine Features Between Obese and Non-Obese Subjects with Polycystic Ovary Syndrome: An Analysis of 263 Consecutive Cases," Clinical Endocrinology, vol. 32, no. 2, pp. 213-220, Feb. 1990.
[25] R. K. Meier, "Polycystic Ovary Syndrome," Nursing Clinics, vol. 53, no. 3, pp. 407-420, Sep. 1, 2018.
[26] M. Olszanecka-Glinianowicz, D. Kuglin, A. Dąbkowska-Huć, and P. Skałba, "Serum Adiponectin and Resistin in Relation to Insulin Resistance and Markers of Hyperandrogenism in Lean and Obese Women with Polycystic Ovary Syndrome," European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 154, no. 1, pp. 51-56, Jan. 1, 2011.